Jonathan Wolleben
Stock Analyst at Citizens Capital Markets
(3.90)
# 583
Out of 4,784 analysts
200
Total ratings
45.69%
Success rate
10.3%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Reiterates: Market Outperform | $19 | $11.97 | +58.73% | 3 | Mar 26, 2025 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $21 → $19 | $5.90 | +221.77% | 7 | Mar 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $1.96 | +667.26% | 2 | Mar 21, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $5.41 | +362.53% | 11 | Mar 14, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $61 | $49.61 | +22.96% | 11 | Mar 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $22 → $19 | $7.62 | +149.51% | 17 | Mar 4, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $10 | $6.29 | +58.91% | 13 | Mar 4, 2025 | |
| PHVS Pharvaris | Reiterates: Market Outperform | $55 | $15.73 | +249.65% | 11 | Mar 3, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Market Outperform | $18 | $7.74 | +132.71% | 7 | Mar 3, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Market Outperform | $26 | $5.87 | +342.93% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $87 | $19.15 | +354.31% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $34.21 | +166.00% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $74 | $45.94 | +61.08% | 9 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $427 | $333.55 | +28.02% | 11 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $53.73 | +39.59% | 2 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.81 | +220.28% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $37.04 | +34.99% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $79.30 | +13.49% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $121.66 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.41 | +467.38% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.32 | +836.36% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $572.46 | -15.28% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.23 | +1,183.70% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $3.69 | +767.21% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $2.30 | +986.96% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.64 | +1,150.00% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.99 | +405.04% | 9 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $31.80 | -24.53% | 1 | May 12, 2023 |
KalVista Pharmaceuticals
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $11.97
Upside: +58.73%
Aura Biosciences
Mar 26, 2025
Maintains: Market Outperform
Price Target: $21 → $19
Current: $5.90
Upside: +221.77%
Skye Bioscience
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.96
Upside: +667.26%
Altimmune
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $5.41
Upside: +362.53%
Protagonist Therapeutics
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $49.61
Upside: +22.96%
Ocular Therapeutix
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $7.62
Upside: +149.51%
DBV Technologies
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $6.29
Upside: +58.91%
Pharvaris
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $15.73
Upside: +249.65%
BioCryst Pharmaceuticals
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.74
Upside: +132.71%
Astria Therapeutics
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $5.87
Upside: +342.93%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $91 → $87
Current: $19.15
Upside: +354.31%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $34.21
Upside: +166.00%
Feb 24, 2025
Reiterates: Market Outperform
Price Target: $74
Current: $45.94
Upside: +61.08%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $427
Current: $333.55
Upside: +28.02%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $53.73
Upside: +39.59%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.81
Upside: +220.28%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $37.04
Upside: +34.99%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $79.30
Upside: +13.49%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $121.66
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.41
Upside: +467.38%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $3
Current: $0.32
Upside: +836.36%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $572.46
Upside: -15.28%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.23
Upside: +1,183.70%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $3.69
Upside: +767.21%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $2.30
Upside: +986.96%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.64
Upside: +1,150.00%
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.99
Upside: +405.04%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $31.80
Upside: -24.53%